Brincidofovir
Phase 1Completed 0 watching 0 views this week💤 Quiet
25
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Smallpox
Conditions
Smallpox
Trial Timeline
May 30, 2023 → Sep 27, 2023
NCT ID
NCT05935917About Brincidofovir
Brincidofovir is a phase 1 stage product being developed by Emergent BioSolutions for Smallpox. The current trial status is completed. This product is registered under clinical trial identifier NCT05935917. Target conditions include Smallpox.
Hype Score Breakdown
Clinical
10
Activity
5
Company
2
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05935917 | Phase 1 | Completed |
Competing Products
20 competing products in Smallpox